Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Dexamethasone vs Bevacizumab for BRVO
NCT04601688Unknown
- Sponsor
- He Eye Hospital
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dexamethasone in branch retinal vein occlusion (BRVO) (2 arms), sponsored by He Eye Hospital. Primary endpoints: Mean change in monocular Best Corrected Visual Acuity at 6 months and Mean change in binocular Best Corrected Visual Acuity at 6 months. Status: unknown.
02
Drugs
dexamethasone
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT04601688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601688.